NDAORALTABLETPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CABOMETYX (cabozantinib) is an oral small-molecule tyrosine kinase inhibitor approved by the FDA in April 2016 for metastatic medullary thyroid cancer (MTC). The drug works by inhibiting multiple receptor tyrosine kinases including RET, MET, VEGFR-1/-2/-3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2, which are implicated in oncogenesis, metastasis, tumor angiogenesis, and drug resistance. As a potent multi-targeted kinase inhibitor, CABOMETYX represents a significant advancement for patients with MTC, a rare but aggressive endocrine malignancy with limited treatment options.
$1.1BPart D
7.2 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
Started Aug 2026
30 enrolled
Neurofibromatosis 1Plexiform Neurofibroma
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Started Apr 2026
234 enrolled
Advanced Renal Cell Carcinoma (RCC)
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Started Mar 2026
16 enrolled
Clear Cell Renal Cell Carcinoma
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Started Dec 2025
150 enrolled
Neuroendocrine Tumors
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Started Sep 2025
720 enrolled
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
Worked on CABOMETYX at Exelixis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.